Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug 19, 2022
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy...
-
Aug 18, 2022
With this recommendation, eligible patients in England, Wales and Northern Ireland will be able to access the first orally administered therapy for GPA/MPA, two main forms of ANCA-associated...
-
Aug 2, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR All regulatory clearances received for the acquisition of Vifor Pharma AG Settlement of the offer is scheduled for 9 August 2022 Seasoned biopharma...
-
Jul 13, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia, and St. Gallen, Switzerland, 13 July 2022 – CSL Limited (ASX: CSL; USOTC:CSLLY) today announced an update regarding the Vifor...
-
May 12, 2022
St. Gallen, Switzerland, 12 May 2022 – CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to...